Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune secrets of tuberculosis to find better treatments

NCT ID NCT07638670

Knowledge-focused Sponsor: First Affiliated Hospital of Ningbo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how different types of mycobacterial infections, including drug-resistant tuberculosis and nontuberculous mycobacteria, change the body's immune response. Researchers will collect blood and other samples from 120 participants, including healthy people and those with active or latent infections. By analyzing immune cells in detail, they hope to uncover new ways to personalize treatment for these serious infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal new immune targets for personalized treatments of tuberculosis and other mycobacterial infections.
What could go wrong
This is an early-stage observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with clinical diagnosis including (active tuberculosis, latent tuberculosis, multidrug-resistant tuberculosis, tuberculous pleurisy, nontuberculous mycobacteria), older than 18 years, meeting the inclusion criteria and no exclusion criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria and Exclusion Criteria: Inclusion Criteria： 1. Age ≥ 18 years, all genders and races accepted. 2. Patients with active pulmonary tuberculosis diagnosed clinically or by bronchoscopy within less than 1 week. 3. Patients with latent tuberculosis infection (positive T-SPOT test but no evidence of active tuberculosis infection). 4. Patients with tuberculous pleurisy with onset within less than 1 week. 5. Voluntarily join this study and sign the informed consent form. 6. Patients whose drug susceptibility test or NGS results indicate resistance to at least isoniazid and rifampicin (MDR-TB). 7. Patients whose drug susceptibility test or NGS results indicate sensitivity to first-line anti-tuberculosis drugs. 8. Patients whose drug susceptibility test or NGS results indicate resistance to only one anti-tuberculosis drug. 9. Patients with newly identified nontuberculous mycobacterial infection (within less than 1 week) by sputum culture or NGS. Exclusion Criteria： 1. Immunosuppressive conditions including HIV infection, long-term use (\>1 month) of immunosuppressive agents or corticosteroids, severe malnutrition, etc. 2. Concurrent other lung diseases, severe liver or kidney dysfunction, severe endocrine diseases, hematological diseases, or malignant tumors that may affect the study outcomes. 3. Patients with diabetes mellitus. 4. Pregnant or lactating women. 5. Patients unable or unwilling to provide informed consent, or with poor compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active pulmonary tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

active tuberculosis latent tuberculosis infection multidrug-resistant tuberculosis pleural tuberculosis pulmonary non-tuberculous mycobacterial infection pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Ningbo University

    RECRUITING

    Ningbo, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.